Blood cancers

DCEP regimen buys time for multiple myeloma patients


The combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) is an effective bridge to autologous stem cell transplant (ASCT) or novel agents in patients with relapsed refractory multiple myeloma.

According to a retrospective review of 65 patients receiving the combination at Alfred Health and Monash Medical Centre between 2005 and 2017, the overall response rate was 55.2%.

“An additional 5% achieved minimal response and 14% achieved stable disease,” the study said.

“Considering many patients were treatment refractory with progressive disease, even stable disease can be considered a desirable endpoint enabling further therapy.”

Response rates were higher in patients using DCEP with thalidomide (57.1%), lenalidomide (72.7%) or bortezomib and thalidomide (100%).

However progression-free survival was a short two months and median overall survival was 9.6 months with DCEP alone or when combined with the other drugs.

Patients who bridged to ASCT had a significantly improved overall survival than those who bridged to other therapy (23.8 v 10.7 months).

“This study demonstrates that DCEP is a valid treatment option for relapsed refractory multiple myeloma with an acceptable ORR of 55% albeit with a rather short PFS. This suggests the role of DCEP should be for bridging to more definitive therapy such as ASCT, novel therapies, or enrollment in a clinical trial.”

Dr Grigoriadis

Haematologist Dr George Grigoriadis, from Monash and Alfred Health, told the limbic most clinicians were using proteosome inhibitor-based regimens up front now.

“But occasionally patients don’t respond or they have progressive disease or they have had explosive disease that almost looks like a high-grade lymphoma.”

“And DCEP is often the go-to regimen that we have been using at the Alfred and at Monash to curtail that growth and allow us an opportunity to get the disease under control, re-introduce a novel agent or proceed to a first or second transplant.”

“As with anything, it’s about buying time.”

He said the treatment landscape has changed significantly since the study period.

“We have many, many more therapies available to us that we know are very effective and efficient and able to keep the disease in control, such as carfilzomib.”

“And that’s a great agent. One of the things you could do is DCEP the patients and then subsequently put them on carfilzomib indefinitely until disease progression.”

The study found adverse events were mainly neutropenia, anemia and thrombocytopenia with febrile neutropenia accounting for five deaths. Overall treatment-related mortality was 9.7%.

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic